Puff Puff Post

SEPTEMBER 16, 2019

Media are invited to attend an open house to learn more about the program and visit the recently expanded Santé Cannabis clinic and research centre in Montréal including a guided tour. Event details below: Date: Tuesday, September 17th 2019. 71,000+ interactions with healthcare professionals. Time: 9:00AM to 5:00PM.

Programs 108

Programs Research and Development Education Treatment 108

Project CBD

FEBRUARY 28, 2023

In December 2021, Leafreport, an online CBD resource owned by Empire Media Network, published the results of analyses of 221 CBD products it sent to third-party laboratories for testing. Available at: www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JUNE 7, 2021

Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Media Contact: Will Johnson. Investor Contact: Brett Maas. 646-536-7331. brett@haydenir.com www.haydenir.com.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Cannabis Law Report

JULY 9, 2021

Clinical trials involving psychedelic drugs and substances are, however, permitted, provided they comply with both state and federal laws applicable to such trials. For further information: For media inquiries: Contact Jonathan McGuire, Assistant Vice President, Corporate Communications, Horizons ETFs Management (Canada) Inc.,

Data 105

Data Clinical Trials Decriminalization Hemp 105

SpeedWeed

AUGUST 16, 2021

LAS VEGAS, NV [August 16, 2021] – Cannabis Conference , produced by parent company GIE Media Inc. Cannabis Conference 2021, presented by the award-winning Cannabis Business Times, Cannabis Dispensary, and Hemp Grower media brands, is the leading educational provider for plant-touching businesses in the legal cannabis and hemp markets.

Media 52

Media Clinical Trials DEA Hemp 52

Cannabis Law Report

JANUARY 12, 2022

“This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.” Andrea Small-Howard, President and Chief Science Officer of Gb Sciences.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

JULY 7, 2021

Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Media Contact: Will Johnson. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 81

Pharmaceutical Data Clinical Trials Research and Development 81

Cannabis Law Report

DECEMBER 9, 2021

Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

MARCH 29, 2020

At an HIV Community Cannabis Education event held in Toronto, a cannabis company proudly declared their company had not had a single product recall to date. Others have faced the wrath of their consumers, media, and everyone in their supply chain networks for not complying with Health Canada’s standards and the Cannabis Act.

Compliance 69

Compliance Compliance Supply Chain Research and Development 69

Cannabis Law Report

JANUARY 13, 2020

Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020. Execute NHIE clinical program utilizing an intravenous formulation of cannabidiol. Media Enquiries: Sam Brown Inc. media enquiries.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Topical 40

Cannabis Law Report

OCTOBER 5, 2021

Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Media: media@mymd.com. Investor: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Media 40

Cannabis Law Report

OCTOBER 17, 2019

The introduction of these protocols will take the form of clinical trials and research that will include the usage of specific strains of cannabis that aid in chronic pain and cancer treatments. Media Relations. Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Media coverage of the paper led to a new stigma and political pressure ended the Spain MDMA study. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JANUARY 6, 2022

Scott will work closely with the management team to further develop the company’s internal and external communications with a focus on strategy, branding, social media presence and investor communications.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

SEPTEMBER 20, 2021

Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from psychedelic treatment for a variety of mental health conditions. Transaction Highlights. Established history of providing ketamine infusion services: The management team at KWC has been in ?

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

SEPTEMBER 22, 2021

Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. Media Contact: media@mymd.com. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40

Cannabis Law Report

OCTOBER 12, 2021

Their audacious vision to reimagine traditional pharma efficacy trials promises to rapidly and accurately determine which nutraceuticals and natural molecules actually work for which conditions,” said Diamandis. Media Contact: Eric Schudiske ( eric@s2spr.com ). What we’ve accomplished thus far is only the beginning!”.

Clinical Trials 40

Clinical Trials Research and Development Sleep Cannabinoids 40

MMJ Recs

JULY 3, 2024

From the pressures of work and personal relationships to the constant bombardment of information on social media and the news, many individuals find themselves struggling to cope with these challenges. We live in a fast-paced world making anxiety and stress become a pervasive issue affecting the mental health of many US citizens.

CBD 52

CBD Research and Development Clinical Trials THC 52

Cannabis Law Report

DECEMBER 28, 2021

Upon completion of all the required IND enabling studies and subsequent review by the FDA, Virpax intends to conduct a Phase 1 study to evaluate the relative bioavailability and pharmacokinetics of Epoladerm™ Virpax recently announced the execution of a clinical trial agreement with Altasciences Company, Inc., Christopher M.

Pharmaceutical 40

Pharmaceutical Research and Development Clinical Trials Chronic Pain 40

Cannabis Law Report

NOVEMBER 24, 2019

Upcoming Events. Dr. Griffiths and Dr. Johnson will be speaking at Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks conference in Washington DC. The award is in part based on his media appearances regarding psychedelic research. SMOKING CESSATION. ANOREXIA NERVOSA.

Therapy 59

Therapy Treatment Medicine Clinical Trials 59

Puff Puff Post

SEPTEMBER 16, 2019

Media are invited to attend an open house to learn more about the program and visit the recently expanded Santé Cannabis clinic and research centre in Montréal including a guided tour. Event details below: Date: Tuesday, September 17th 2019. 71,000+ interactions with healthcare professionals. Time: 9:00AM to 5:00PM.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

NOVEMBER 10, 2021

The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Media: Laura Radocaj. Christopher M. Chipman, CPA. Chief Financial Officer. cchipman@virpaxpharma.com 610-727-4597. Betsy Brod. Affinity Growth Advisors. 212-825-3210.

Research and Development 40

Research and Development Chronic Pain Pharmaceutical Clinical Trials 40

Cannabis Law Report

FEBRUARY 28, 2020

The combination of experience, wisdom and the optimism of the recent entrants is positively intoxicating, and has created an exciting buzz at events, but there will be bumps along the road and we should expect teething problems. Events were full of people talking about how this technology would revolutionise everything.

Law 59

Law Research and Development Recreational Cannabis 59

Cannabis Law Report

JULY 15, 2022

Sunshine Coast based Tikun Oceana, formerly known as Medifarm , is now under the control of administrators from Cor Cordis.The company was founded …… Predictably Murdoch media has this behind a paywall if you want to pay to learn more. Media event date: 27 August 2019. Media type: Transcript. Read more at.

Medicine 52

Medicine Patients Media Supply Chain 52

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K.

Therapy 40

Therapy Research and Development Business Access 40

Cannabis Law Report

NOVEMBER 24, 2021

Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. This article analyses media representations of medicinal cannabis in Australian medical publications. Media framing of cannabis.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

AUGUST 10, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. Media Contact: Will Johnson. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Clinical Trials 105

Clinical Trials Pharmaceutical Research and Development CBD 105

Cannabis Law Report

JULY 8, 2021

These statements relate to future events or future performance. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Treatment 98

Treatment Clinical Trials CBD Patients 98

Cannabis Law Report

SEPTEMBER 24, 2019

We are very happy that patients will now have access to a much-needed, new treatment option, and one routed through a rigorous clinical trials programme and licensed by the EMA.”. All investor and media enquiries. media enquiries. media enquiries. Forward-looking statements. publicrelations@gwpharm.com.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

NORML

SEPTEMBER 20, 2019

But at the Vegas event, she brought good news: She announced that other universities would host her research, and she recently applied for a third-party cultivation license from the DEA, the only federal agency that can legally provide cannabis for clinical study in the US.

DEA 251

DEA Research and Development Clinical Trials Patients 251

Cannabis Law Report

JUNE 4, 2021

Our proprietary ranking system takes into account: Social reach (social media, blogs, podcasts, publications, etc.). Through his social media outlets, podcast, blog, and interviews, Tim has educated hundreds of millions of people about psychedelics. This list is focused on those who have had the largest impact for 2021. . Followers.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51